



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Application Number	09/891,602
Filing Date	June 26, 2001
First Named Inventor	Dyatkin
Group Art Unit	1625
Examiner Name	C. Aulakh
Attorney Docket Number	ORT-1451

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature	AULAKH	Date Considered	9-4-02
-----------------------	--------	--------------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conflict.

7-5-02	Considered	9-4-02
--------	------------	--------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Examiner Signature	AWLAKH	Date Considered	9-4-02
-----------------------	--------	--------------------	--------



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Application Number	09/891,602
Filing Date	June 26, 2001
First Named Inventor	Dyatkin
Group Art Unit	1625
Examiner Name	C. Aulakh
Attorney Docket Number	ORT-1451

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
CA		Osborn, L.; et al., Cell, 1989, 59, 1203	
CA		Wayner, E. A.; et al., Cell Biol., 1989, 109, 1321	
CA		Bayless, K. J.; et al., J. Cell Sci., 1998, 111, 1165	
CA		Adams, S. P.; et al., Ann. Rep. Med. Chem., 1999, 34, 179	
CA		Chuluyan, H. E.; et al., Springer Semin. Immunopathol., 1995, 16, 391	
CA		Simmons, P. J.; et al., Blood, 1992, 80, 388	
CA		Shroff, H. N.; et al., Bioorg. Med. Chem. Lett., 1998, 8, 1601	
CA		Yoshikawa, H.; et al., J. Immunol., 1996, 156, 1832	
CA		Laberge, S.; et al., Am. J. Respir. Crit. Care Med., 1995, 151, 822	
CA		Barbadillo, C.; et al., Springer Semin. Immunopathol., 1995, 16, 375	
CA		Powrie, F.; et al., Ther. Immunol., 1995, 2, 115	
CA		Tamraz, S.; et al., Springer Semin. Immunopathol. 1995, 16, 437	
CA		Molossi, S.; et al., J. Clin. Invest. 1995, 95, 2601	
CA		Lin, K-C.; et al., J. Med. Chem. 1999, 42, 920	
CA		Kling D, Fingerle J, Harlan JM, Lobb, RR and Lang, F, Mononuclear leukocytes invade rabbit arterial intima during thickening formation via CD-18 and VLA-4-dependent mechanisms and stimulate smooth muscle migration, Circ. Res., 1995, 77, 1121-1128	
CA		Lumsden AB, Chen C, Hughes JD, Kelly AB, Hanson S and Harker L, Anti-VLA-4 antibody reduces intimal hyperplasia in the endarterectomized carotid artery in non-human primates, J. Vasc. Surg., 1997, 26, 87-93	
CA		Labinez M, Hoffert C, pels K, Aggarawal S, Pepinsky RB, Leonw D, Koteliensky V, Lobb, RR and O'Brien EO, Infusion on and anti-alpha4 integrin antibody is associated with less adventitial formation after balloon injury of porcine coronary arteries, Can. J. Cardiol., 2000, 16, 187-196	
CA		O'Brien KD, Allen MD, McDonald TO, Chait A, Harlan JM, Fishbein D, McCarty J, Ferguson M, Hudkins K, Benjamin CD, et al., Vascular cell adhesion molecule-1 is expressed in human atherosclerotic plaques: implications for the mode of progression of advanced atherosclerosis, J. Clin. Invest., 1993, 92, 945-951	
CA		Nakahima Y, Raines EW, Plump AS, Breslow JL and Ross R, Upregulation of VCAM-1 and ICAM-1 at atherosclerotic-prone sites on the endothelium of ApoE-deficient mouse, Arterioscler. Thromb. Vasc. Biol., 1998, 18, 842-851	
CA		Iiyama K, Hajra L, Iiyam M, Li, H, DiChura M, Medoff BD and Cybulsky MI, Patterns of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 expression in rabbit and mouse atherosclerotic lesion and at sites predisposed to lesion formation, Circ. Res., 1999, 85, 199-207	
CA		Shih PT, Brennan M-L, Vora DK, Territo MC, Strahl D, Elices MJ, Aldons J and Berliner JA, Blocking very late antigen-4 integrin decreases leukocyte entry and fatty streak formation in mice fed an atherogenic diet, Circ. Res., 1999, 84, 345-351	
CA		Huo Y, Hafez-Moghadem A and Ley K, Role of vascular cell adhesion molecule-1 and fibronectin connecting segment-1 in monocyte rolling and adhesion on early atherosclerotic lesions, Circ. Res., 2000, 87, 153-159	
CA		Hamann, A.; et al., J. Immunol. 1994, 152, 3282	
CA		Hanninen, A.C.; et al., J. Clin. Invest. 1993, 92, 2509	
CA		Fong, S.; et al., Immunol. Res. 1997, 16, 299	
CA		Yang, X.; et al., Diabetes 1997, 46, 1542	
CA		Gould, Philip L., Ref. International J. Pharm., 1986, 33, 201-217	
CA		Berge et al., J. Pharm.Sci., 1997 (Jan), 66, 1, 1	

Examiner Signature	AULAKH	Date Considered	9-4-02
--------------------	--------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.